Dengue virus therapeutic intervention strategies based on viral, vector and host factors involved in disease pathogenesis

Pharmacology and Therapeutics

Volumn 137, Issue 2, 2013, Pages 266-282

  Herrero, Lara J ^a,b   Zakhary, Andrew ^b   Gahan, Michelle E ^b   Nelson, Michelle A ^b   Herring, Belinda L ^a   Hapel, Andrew J ^b   Keller, Paul A ^c   Obeysekera, Maheshi ^a   Chen, Weiqiang ^a   Sheng, Kuo Ching ^a   Taylor, Adam ^a   Wolf, Stefan ^a   Bettadapura, Jayaram ^a,b   Broor, Shobha ^d   Dar, Lalit ^d   Mahalingam, Suresh ^a,b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF CANBERRA   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Arbovirus; Dengue virus; Disease severity; Flavivirus; Immunity; Pathogenesis

Indexed keywords

ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE 1; ANTISENSE OLIGONUCLEOTIDE; CD209 ANTIGEN; CHIMERIVAX; CLEC5A PROTEIN; CYTOKINE; D1ME VR P; DEN 80E; DENGUE VACCINE; DENGUE VIRUS PROTEIN; DENVAX; HOST FACTOR; LAV (DRUG); LECTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MANNOSE RECEPTOR; METHYLTRANSFERASE; NONSTRUCTURAL PROTEIN 1; NUCLEOTIDE; PHOSPHOTRANSFERASE INHIBITOR; RNA POLYMERASE; SERINE PROTEINASE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ALLELE; ANTIBODY RESPONSE; BLEEDING; DENGUE; DENGUE VIRUS; GENOTYPE; HOST; HUMAN; IMMUNE RESPONSE; INHIBITION KINETICS; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE METABOLISM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEROTYPE; THROMBOCYTOPENIA; VASCULAR DISEASE; VASCULAR LEAKAGE; VIROGENESIS; VIRUS ENTRY;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; GENETIC PREDISPOSITION TO DISEASE; HOST-DERIVED CELLULAR FACTORS; HUMANS; INSECT VECTORS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84872760403     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.10.007     Document Type: Review

References (216)

1. B. Acioli-Santos, L. Segat, R. Dhalia, C.A. Brito, U.M. Braga-Neto, and E.T. Marques MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue phenotype Hum Immunol 69 2008 122 128
2. E.G. Acosta, V. Castilla, and E.B. Damonte Alternative infectious entry pathways for dengue virus serotypes into mammalian cells Cell Microbiol 11 2009 1533 1549
3. M.M.F. Alen, T. De Burghgraeve, S.J.F. Kaptein, J. Balzarini, J. Neyts, and D. Schols Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells PLoS One 6 2011 e21658
4. M.M.F. Alen, S.J.F. Kaptein, T. De Burghgraeve, J. Balzarini, J. Neyts, and D. Schols Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection Virology 387 2009 67 75
5. A.C. Allison, and E.M. Eugui Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 2000 85 118
6. J. An, J. Kimura-Kuroda, Y. Hirabayashi, and K. Yasui Development of a novel mouse model for dengue virus infection Virology 263 1999 70 77
7. S. Anantapreecha, S. Chanama, A. A-nuegoonpipat, S. Naemkhunthot, A. Sa-Ngasang, and P. Sawanpanyalert Serological and virological features of dengue fever and dengue haemorrhagic fever in Thailand from 1999 to 2002 Epidemiol Infect 133 2005 503 507
8. B.J. Appelmelk, I. van Die, S.J. van Vliet, C.M.J.E. Vandenbroucke- Grauls, T.B.H. Geijtenbeek, and Y. van Kooyk Cutting edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells J Immunol 170 2003 1635 1639
9. I. Assunção-Miranda, F.A. Amaral, F.A. Bozza, C.T. Fagundes, L.P. Sousa, and D.G. Souza Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection FASEB J 24 2010 218 228
10. P. Avirutnan, P. Malasit, B. Seliger, S. Bhakdi, and M. Husmann Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis 1 J Immunol 161 1998 6338 6346
11. P. Avirutnan, N. Punyadee, S. Noisakran, C. Komoltri, S. Thiemmeca, and K. Auethavornanan Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement J Infect Dis 193 2006 1078 1088
12. A.B.H. Bakker, E. Baker, G.R. Sutherland, J.H. Phillips, and L.L. Lanier Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells Proc Natl Acad Sci U S A 96 1999 9792 9796
13. K.K. Ballenger-Browning, and J.P. Elder Multi-modal Aedes aegypti mosquito reduction interventions and dengue fever prevention Trop Med Int Health 14 2009 1542 1551
14. A. Balmaseda, S.N. Hammond, L. Perez, Y. Tellez, S.I. Saborio, and J.C. Mercado Serotype-specific differences in clinical manifestations of dengue Am J Trop Med Hyg 74 2006 449 456
15. S.J. Balsitis, J. Coloma, G. Castro, A. Alava, D. Flores, and J.H. McKerrow Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining Am J Trop Med Hyg 80 2009 416 424
16. S.J. Balsitis, K.L. Williams, R. Lachica, D. Flores, J.L. Kyle, and E. Mehlhop Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification PLoS Pathog 6 2010 e1000790
17. J. Balzarini, S. Hatse, K. Vermeire, K. Princen, S. Aquaro, and C.F. Perno Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection Antimicrob Agents Chemother 48 2004 3858 3870
18. J. Balzarini, K. Van Laethem, S. Hatse, M. Froeyen, W. Peumans, and E. Van Damme Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120 J Biol Chem 280 2005 41005 41014
19. A. Basu, and U.C. Chaturvedi Vascular endothelium: the battlefield of dengue viruses FEMS Immunol Med Microbiol 53 2008 287 299
20. C.G. Beckett, J. Tjaden, T. Burgess, J.R. Danko, C. Tamminga, and M. Simmons Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial Vaccine 29 2011 960 968
21. M. Beltramello, K.L. Williams, C.P. Simmons, A. Macagno, L. Simonelli, and N.T. Quyen The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity Cell Host Microbe 8 2010 271 283
22. D. Benarroch, M.P. Egloff, L. Mulard, C. Guerreiro, J.L. Romette, and B. Canard A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate J Biol Chem 279 2004 35638 35643
23. D.A. Bente, M.W. Melkus, J.V. Garcia, and R. Rico-Hesse Dengue fever in humanized NOD/SCID mice J Virol 79 2005 13797 13799
24. J. Bernhagen, R. Krohn, H. Lue, J.L. Gregory, A. Zernecke, and R.R. Koenen MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment Nat Med 13 2007 587 596
25. C. Bertaux, D. Daelemans, L. Meertens, E.G. Cormier, J.F. Reinus, and W.J. Peumans Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions Virology 366 2007 40 50
26. P.T. Binh, S. Matheus, V.T.Q. Huong, X. Deparis, and V. Marechal Early clinical and biological features of severe clinical manifestations of dengue in Vietnamese adults J Clin Virol 45 2009 276 280
27. H.H. Biswas, O. Ortega, A. Gordon, K. Standish, A. Balmaseda, and G. Kuan Early clinical features of dengue virus infection in Nicaraguan children: a longitudinal analysis PLoS Negl Trop Dis 6 2012 e1562
28. K. Boonnak, K.M. Dambach, G.C. Donofrio, B. Tassaneetrithep, and M.A. Marovich Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection J Virol 85 2011 1671 1683
29. S. Boonpucknavig, O. Vuttiviroj, C. Bunnag, N. Bhamarapravati, and S. Nimmanitya Demonstration of dengue antibody complexes on the surface of platelets from patients with dengue hemorrhagic fever Am J Trop Med Hyg 28 1979 881 884
30. S. Brandler, M. Lucas-Hourani, A. Moris, M.P. Frenkiel, C. Combredet, and M. Fevrier Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus PLoS Negl Trop Dis 1 2007 e96
31. T. Calandra, J. Bernhagen, C.N. Metz, L.A. Spiegel, M. Bacher, and T. Donnelly MIF as a glucocorticoid-induced modulator of cytokine production Nature 377 1995 68 71
32. T. Calandra, and T. Roger Macrophage migration inhibitory factor: a regulator of innate immunity Nat Rev Immunol 3 2003 791 800
33. E.P. Caragata, and T. Walker Using bacteria to treat diseases Expert Opin Biol Ther 12 2012 701 712
34. T.H. Chang, C.L. Liao, and Y.L. Lin Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation Microbes Infect 8 2006 157 171
35. S. Chanprapaph, P. Saparpakorn, C. Sangma, P. Niyomrattanakit, S. Hannongbua, and C. Angsuthanasombat Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites Biochem Biophys Res Commun 330 2005 1237 1246
36. L. Chen, D. Ewing, H. Subramanian, K. Block, J. Rayner, and K.D. Alterson A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques J Virol 81 2007 11634 11639
37. L.C. Chen, H.Y. Lei, C.C. Liu, S.C. Shiesh, S.H. Chen, and H.S. Liu Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients Am J Trop Med Hyg 74 2006 142 147
38. S.-T. Chen, Y.-L. Lin, M.-T. Huang, M.-F. Wu, S.-C. Cheng, and H.-Y. Lei CLEC5A is critical for dengue-virus-induced lethal disease Nature 453 2008 672 676
39. Y. Chen, T. Maguire, R.E. Hileman, J.R. Fromm, J.D. Esko, and R.J. Linhardt Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate Nat Med 3 1997 866 871
40. Y.-C. Chen, and S.-Y. Wang Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide J Virol 76 2002 9877 9887
41. R. Cheung, F. Shen, J.H. Phillips, M.J. McGeachy, D.J. Cua, and P.G. Heyworth Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice J Clin Invest 121 2011 4446 4461
42. C.Y. Chiang, S.J. Liu, J.P. Tsai, Y.S. Li, M.Y. Chen, and H.H. Liu A novel single-dose dengue subunit vaccine induces memory immune responses PLoS One 6 2011 e23319
43. J.J. Chu, and P.L. Yang c-Src protein kinase inhibitors block assembly and maturation of dengue virus Proc Natl Acad Sci U S A 104 2007 3520 3525
44. Y.C. Chuang, H.Y. Lei, H.S. Liu, Y.S. Lin, T.F. Fu, and T.M. Yeh Macrophage migration inhibitory factor induced by dengue virus infection increases vascular permeability Cytokine 54 2011 222 231
45. D.E. Clements, B.A. Coller, M.M. Lieberman, S. Ogata, G. Wang, and K.E. Harada Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys Vaccine 28 2010 2705 2715
46. B.A. Coller, and D.E. Clements Dengue vaccines: progress and challenges Curr Opin Immunol 23 3 2011 391 398
47. K. Clyde, J.L. Kyle, and E. Harris Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis J Virol 80 2006 11418 11431
48. B.A. Coller, D.E. Clements, A.J. Bett, S.L. Sagar, and J.H. Ter Meulen The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease Vaccine 29 2011 7267 7275
49. R. Cologna, P.M. Armstrong, and R. Rico-Hesse Selection for virulent dengue viruses occurs in humans and mosquitoes J Virol 79 2005 853 859
50. R. Cologna, and R. Rico-Hesse American genotype structures decrease dengue virus output from human monocytes and dendritic cells J Virol 77 2003 3929 3938
51. J. Cox, H.E. Brown, and R. Rico-Hesse Variation in vector competence for dengue viruses does not depend on mosquito midgut binding affinity PLoS Negl Trop Dis 5 2011 e1172
52. J.M. Crance, N. Scaramozzino, A. Jouan, and D. Garin Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses Antiviral Res 58 2003 73 79
53. W.D. Crill, and G.J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes J Virol 78 2004 13975 13986
54. A.L. Cunningham, A.N. Harman, and H. Donaghy DC-SIGN 'AIDS' HIV immune evasion and infection Nat Immunol 8 2007 556 558
55. R.A.C. de Castro, J.-A.A. De Castro, M.Y.C. Barez, M.V. Frias, J. Dixit, and M. Genereux Thrombocytopenia Associated With Dengue Hemorrhagic Fever Responds To Intravenous Administration Of Anti-D (Rh0-D) Immune Globulin Am J Trop Med Hyg 76 2007 737 742
56. E. De Clercq, M. Cools, J. Balzarini, R. Snoeck, G. Andrei, and M. Hosoya Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds Antimicrob Agents Chemother 35 1991 679 684
57. B.E. Dewi, T. Takasaki, and I. Kurane In vitro assessment of human endothelial cell permeability: effects of inflammatory cytokines and dengue virus infection J Virol Methods 121 2004 171 180
58. M.S. Diamond, M. Zachariah, and E. Harris Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA Virology 304 2002 211 221
59. K. Djamiatun, A.J.A.M. van der Ven, P.G. de Groot, S.M.H. Faradz, D. Hapsari, and W.M.V. Dolmans Severe dengue is associated with consumption of von willebrand factor and its cleaving enzyme ADAMTS-13 PLoS Negl Trop Dis 6 2012 e1628
60. Y. Dong, J.C. Morton Jr., J.L. Ramirez, J.A. Souza-Neto, and G. Dimopoulos The entomopathogenic fungus Beauveria bassiana activate toll and JAK-STAT pathway-controlled effector genes and anti-dengue activity in Aedes aegypti Insect Biochem Mol Biol 42 2012 126 132
61. S.C. Donnelly, and R. Bucala Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease Mol Med Today 3 1997 502 507
62. A.P. Durbin, A. Schmidt, D. Elwood, K.A. Wanionek, J. Lovchik, and B. Thumar Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic J Infect Dis 203 2011 327 334
63. R. Edelman Dengue vaccines approach the finish line Clin Infect Dis 45 2007 S56 S60
64. R. Edelman, S.S. Wasserman, S.A. Bodison, R.J. Putnak, K.H. Eckels, and D. Tang Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine Am J Trop Med Hyg 69 2003 48 60
65. A. Engering, T.B.H. Geijtenbeek, S.J. van Vliet, M. Wijers, E. van Liempt, and N. Demaurex The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells J Immunol 168 2002 2118 2126
66. A.K. Erickson, and M. Gale Jr. Regulation of interferon production and innate antiviral immunity through translational control of IRF-7 Cell Res 18 2008 433 435
67. C.T. Fagundes, V.V. Costa, D. Cisalpino, D.G. Souza, and M.M. Teixeira Therapeutic opportunities in dengue infection Drug Dev Res 72 2011 480 500
68. M.T. Fernandez-Mestre, K. Gendzekhadze, P. Rivas-Vetencourt, and Z. Layrisse TNF-a-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients Tissue Antigens 64 2004 469 472
69. J. Fink, F. Gu, and S.G. Vasudevan Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever Rev Med Virol 16 2006 263 275
70. J.K. Forwood, A. Brooks, L.J. Briggs, C.Y. Xiao, D.A. Jans, and S.G. Vasudevan The 37-amino-acid interdomain of dengue virus NS5 protein contains a functional NLS and inhibitory CK2 site Biochem Biophys Res Commun 257 1999 731 737
71. J.R. Fried, R.V. Gibbons, S. Kalayanarooj, S.J. Thomas, A. Srikiatkhachorn, and I.-K. Yoon Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006 PLoS Negl Trop Dis 4 2010 e617
72. B. Gabrielsen, M.J. Phelan, L. Barthel-Rosa, C. See, J.W. Huggins, and D.F. Kefauver Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride J Med Chem 35 1992 3231 3238
73. C.C. Garcia, R. Guabiraba, F.M. Soriani, and M.M. Teixeira The development of anti-inflammatory drugs for infectious diseases Discov Med 10 2010 479 488
74. K. Ghosh, S. Gangodkar, P. Jain, S. Shetty, S. Ramjee, and P. Poddar Imaging the interaction between dengue 2 virus and human blood platelets using atomic force and electron microscopy J Electron Microsc 57 2008 113
75. J.L. Gregory, E.F. Morand, S.J. McKeown, J.A. Ralph, P. Hall, and Y.H. Yang Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2 J Immunol 177 2006 8072 8079
76. D.J. Gubler Dengue and dengue hemorrhagic fever Clin Microbiol Rev 11 1998 480 496
77. Gudmundsson, K. (2006). Preparation of Carbazoles and Related Compounds for Treatment of Dengue Fever, Yellow Fever, West Nile Virus, and Hepatitis C Virus Infection. Patent 2005-US41091 2006121467 20051114.
78. B. Guy, and J.W. Almond Towards a dengue vaccine: progress to date and remaining challenges Comp Immunol Microbiol Infect Dis 31 2008 239 252
79. B. Guy, J. Almond, and J. Lang Dengue vaccine prospects: a step forward Lancet 377 2011 381 382
80. S.B. Halstead Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission Am J Trop Med Hyg 65 2001 180 183
81. S.B. Halstead Ad Virus Res 60 2003 421 467
82. S. Halstead, and E. O'Rourke Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody J Exp Med 146 1977 201 217
83. A.F. Harris, D. Nimmo, A.R. McKemey, N. Kelly, S. Scaife, and C.A. Donnelly Field performance of engineered male mosquitoes Nat Biotechnol 29 2011 U1034 U1109
84. A. Helenius How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum Mol Biol Cell 5 1994 253 265
85. H. Hettkamp, G. Legler, and E. Bause Purification by affinity chromatography of glucosidase I, an endoplasmic reticulum hydrolase involved in the processing of asparagine-linked oligosaccharides Eur J Biochem 142 1984 85 90
86. K.I. Hidari, and T. Suzuki Antiviral agents targeting glycans on dengue virus E-glycoprotein Expert Rev Anti Infect Ther 9 2011 983 985
87. L.J. Ho, L.F. Hung, C.Y. Weng, W.L. Wu, P. Chou, and Y.L. Lin Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell J Immunol 174 2005 8163 8172
88. S.L. Hung, P.L. Lee, H.W. Chen, L.K. Chen, C.L. Kao, and C.C. King Analysis of the steps involved in Dengue virus entry into host cells Virology 257 1999 156 167
89. J. Imoto, and E. Konishi Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine Vaccine 25 2007 1076 1084
90. M.A. Ingersoll, R. Spanbroek, C. Lottaz, E.L. Gautier, M. Frankenberger, and R. Hoffmann Comparison of gene expression profiles between human and mouse monocyte subsets Blood 115 2010 e10 e19
91. S. Ishii, and T. Shimizu Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice Prog Lipid Res 39 2000 41 82
92. I. Iturbe-Ormaetxe, T. Walker, and O'Neill Wolbachia and the biological control of mosquito-borne disease EMBO Rep 12 2011 508 518
93. M. Jones, A. Davidson, L. Hibbert, P. Gruenwald, J. Schlaak, and S. Ball Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression J Virol 79 2005 5414 5420
94. N. Kanesa-thasan, W. Sun, G. Kim-Ahn, S. Van Albert, J.R. Putnak, and A. King Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers Vaccine 19 2001 3179 3188
95. M. Kapoor, L. Zhang, M. Ramachandra, J. Kusukawa, K.E. Ebner, and R. Padmanabhan Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5 J Biol Chem 270 1995 19100 19106
96. K. Kimura, M. Nagaki, J. Nishihira, S. Satake, K. Kuwata, and H. Moriwaki Role of macrophage migration inhibitory factor in hepatitis B virus-specific cytotoxic-T-lymphocyte-induced liver injury Clin Vaccine Immunol 13 2006 415 419
97. S.C. Kliks, S. Nimmanitya, A. Nisalak, and D.S. Burke Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants Am J Trop Med Hyg 38 1988 411
98. S.C. Kliks, A. Nisalak, W.E. Brandt, L. Wahl, and D.S. Burke Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever Am J Trop Med Hyg 40 1989 444
99. T. Kochel, S.J. Wu, K. Raviprakash, P. Hobart, S. Hoffman, and K. Porter Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice Vaccine 15 1997 547 552
100. E. Konishi, and A. Fujii Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine Vaccine 20 2002 1058 1067
101. G.P. Kouri, M.G. Guzmán, J.R. Bravo, and C. Triana Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981 Bull WHO 67 1989 375 380
102. L.M. Kuitert, R.M. Angus, N.C. Barnes, P.J. Barnes, M.F. Bone, and K.F. Chung Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma Am J Respir Crit Care 151 1995 1331 1335
103. T. Kurosu, P. Chaichana, M. Yamate, S. Anantapreecha, and K. Ikuta Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1 Biochem Biophys Res Commun 362 2007 1051 1056
104. C.Y. Lai, W.Y. Tsai, S.R. Lin, C.L. Kao, H.P. Hu, and C.C. King Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II J Virol 82 2008 6631 6643
105. L. Lambrechts, T.W. Scott, and D.J. Gubler Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission PLoS Negl Trop Dis 4 2010 e646
106. C.H. Lavinder, and E. Francis The etiology of dengue: an attempt to produce the disease in the rhesus monkey by the inoculation of defibrinated blood J Infect Dis 15 1914 341 346
107. C.J. Lee, C.L. Liao, and Y.L. Lin Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection J Virol 79 2005 8388 8399
108. Y. Lee, M. Liu, H. Lei, C. Liu, J. Wu, and Y. Tung MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells J Gen Virol 87 2006 3623
109. K. Leitmeyer, D. Vaughn, D. Watts, R. Salas, and I. Villalobos Dengue virus structural differences that correlate with pathogenesis J Virol 73 1999 4738
110. P. Leyssen, J. Balzarini, E. De Clercq, and J. Neyts The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase J Virol 79 2005 1943 1947
111. D.H. Libraty, P.R. Young, D. Pickering, T.P. Endy, S. Kalayanarooj, and S. Green High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever J Infect Dis 186 2002 1165 1168
112. C. Lin, S. Chiu, Y. Hsiao, S. Wan, H. Lei, and A. Shiau Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1 J Immunol 174 2005 395 403
113. C. Lin, H. Lei, C. Liu, H. Liu, T. Yeh, and S. Wang Generation of IgM anti-platelet autoantibody in dengue patients J Med Virol 63 2001 143 149
114. O. Lisova, F. Hardy, V. Petit, and H. Bedouelle Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus J Gen Virol 88 2007 2387 2397
115. I.J. Liu, C.Y. Chiu, Y.C. Chen, and H.C. Wu Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus J Biol Chem 286 2011 9726 9736
116. P.-Y. Lozach, L. Burleigh, I. Staropoli, E. Navarro-Sanchez, J. Harriague, and J.-L. Virelizier Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection Is independent of DC-SIGN internalization signals J Biol Chem 280 2005 23698 23708
117. I.S. Ludwig, A.N. Lekkerkerker, E. Depla, F. Bosman, R.J.P. Musters, and S. Depraetere Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation J Virol 78 2004 8322 8332
118. D.D. Ma, T. Rede, N.A. Naqvi, and P.D. Cook Synthetic oligonucleotides as therapeutics: the coming of age Biotechnol Annu Rev 5 2000 155 196
119. U. Mabalirajan, T. Kadhiravan, S.K. Sharma, A. Banga, and B. Ghosh Th2 immune response in patients with dengue during defervescence: preliminary evidence Am J Trop Med Hyg 72 2005 783 785
120. B. Marcheco, D.R. Danay Díaz, L. Sánchez, G. García, B. Sierra, and M. Pupo Asymptomatic dengue infection in a cuban population confirms the protective role of the RR variant of the FcγRIIa polymorphism Am J Trop Med Hyg 82 2010 1153 1156
121. R.M. Marks, H. Lu, R. Sundaresan, T. Toida, A. Suzuki, and T. Imanari Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors J Med Chem 44 2001 2178 2187
122. A.M. Marrache, F. Gobeil, S.G. Bernier, J. Stankova, M. Rola-Pleszczynski, and S. Choufani Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor J Immunol 169 2002 6474 6481
123. C.S.-S. Martín, C.Y. Liu, and M. Kielian Dealing with low pH: entry and exit of alphaviruses and flaviviruses Trends Microbiol 17 2009 514 521
124. A. Mathew, and A.L. Rothman Understanding the contribution of cellular immunity to dengue disease pathogenesis Immunol Rev 225 2008 300 313
125. M. Matsumoto, C.L. Bennett, A. Isonishi, Z. Qureshi, Y. Hori, and M. Hayakawa Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan PLoS One 7 2012 e33029
126. M. Mazzon, M. Jones, A. Davidson, B. Chain, and M. Jacobs Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation J Infect Dis 200 2009 1261 1270
127. C.L. Medin, K.A. Fitzgerald, and A.L. Rothman Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion J Virol 79 2005 11053 11061
128. J.L. Miller, B.J.M. deWet, L. Martinez-Pomares, C.M. Radcliffe, R.A. Dwek, and P.M. Rudd The mannose receptor mediates dengue virus infection of macrophages PLoS Pathog 4 2008 e17
129. Brian G. Miller, Thomas W. Traut, and R. Wolfenden Effects of substrate binding determinants in the transition state for orotidine 5′- monophosphate decarboxylase Bioorg Chem 26 1998 283 288
130. G. Montrucchio, G. Alloatti, and G. Camussi Role of platelet-activating factor in cardiovascular pathophysiology Physiol Rev 80 2000 1669 1699
131. D. Morrison, T.J. Legg, C.W. Billings, R. Forrat, S. Yoksan, and J. Lang A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults J Infect Dis 201 2010 370 377
132. J.L. Munoz-Jordan, G.G. Sanchez-Burgos, M. Laurent-Rolle, and A. Garcia-Sastre Inhibition of interferon signaling by dengue virus Proc Natl Acad Sci U S A 100 2003 14333 14338
133. S. Murrell, S.C. Wu, and M. Butler Review of dengue virus and the development of a vaccine Biotechnol Adv 29 2 2011 239 247
134. B.R. Murphy, and S.S. Whitehead Immune response to dengue virus and prospects for a vaccine Annu Rev Immunol 29 2011 587 619
135. H.M. Murthy, K. Judge, L. DeLucas, and R. Padmanabhan Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design J Mol Biol 301 2000 759 767
136. E. Navarro-Sanchez, R. Altmeyer, A. Amara, O. Schwartz, F. Fieschi, and J.-L. Virelizier Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses EMBO Rep 4 2003 723 728
137. E. Navarro-Sanchez, P. Despres, and L. Cedillo-Barron Innate immune responses to dengue virus Arch Med Res 36 2005 425 435
138. V. Nayak, M. Dessau, K. Kucera, K. Anthony, M. Ledizet, and Y. Modis Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion J Virol 83 2009 4338 4344
139. T.P. Nguyen, M. Kikuchi, T.Q. Vu, Q.H. Do, T.T. Tran, and D.T. Vo Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome PLoS Negl Trop Dis 2 2008 e304
140. A. Nisalak, T.P. Endy, S. Nimmannitya, S. Kalayanarooj, U. Thisayakorn, and R.M. Scott Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999 Am J Trop Med Hyg 68 2003 191 202
141. C.G. Noble, Y.-L. Chen, H. Dong, F. Gu, S.P. Lim, and W. Schul Strategies for development of dengue virus inhibitors Antiviral Res 85 2010 450 462
142. K. Oishi, S. Inoue, M. Cinco, E. Dimaano, M. Alera, and J. Alfon Correlation between increased platelet-associated IgG and thrombocytopenia in secondary dengue virus infections J Med Virol 71 2003 259 264
143. D.B. Olsen, A.B. Eldrup, L. Bartholomew, B. Bhat, M.R. Bosserman, and A. Ceccacci A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties Antimicrob Agents Chemother 48 2004 3944 3953
144. J.E. Osorio, J.N. Brewoo, S.J. Silengo, J. Arguello, I.R. Moldovan, and M. Tary-Lehmann Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques Am J Trop Med Hyg 84 2011 978 987
145. C.N. Paiva, R.H. Arras, E.S. Magalhaes, L.S. Alves, L.P. Lessa, and M.H. Silva Migration inhibitory factor (MIF) released by macrophages upon recognition of immune complexes is critical to inflammation in Arthus reaction J Leukoc Biol 85 2009 855 861
146. Y.T. Pan, J. Ghidoni, and A.D. Elbein The effects of castanospermine and swainsonine on the activity and synthesis of intestinal sucrase Arch Biochem Biophys 303 1993 134 144
147. C. Paupy, B. Ollomo, B. Kamgang, S. Moutailler, D. Rousset, and M. Demanou Comparative role of Aedes albopictus and Aedes aegypti in the emergence of Dengue and Chikungunya in central Africa Vector Borne Zoonotic Dis 10 2010 259 266
148. L. Pelkmans, E. Fava, H. Grabner, M. Hannus, B. Habermann, and E. Krausz Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis Nature 436 2005 78 86
149. J. Poo, F. Galan, R. Forrat, B. Zambrano, J. Lang, and G.H. Dayan Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity Pediatr Infect Dis J 30 1 2011 e9 e17
150. O. Puiprom, A. Yamashita, M. Sasayama, K. Limkittikul, K. Boonha, and A. Jittmitraphap Co-existence of major and minor viral populations from two different origins in patients secondarily infected with dengue virus serotype 2 in Bangkok Biochem Biophys Res Commun 413 2011 136 142
151. B. Pulendran Modulating vaccine responses with dendritic cells and Toll-like receptors Immunol Rev 199 2004 227 250
152. K. Raviprakash, D. Wang, D. Ewing, D.H. Holman, K. Block, and J. Woraratanadharm A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus J Virol 82 2008 6927 6934
153. C.R. Rees, J.M. Costin, R.C. Fink, M. McMichael, K.A. Fontaine, and S. Isern In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries Antiviral Res 80 2008 135 142
154. R. Rico-Hesse, L. Harrison, R. Salas, D. Tovar, A. Nisalak, and C. Ramos Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas Virology 230 1997 244 251
155. J. Robert Putnak, B.A. Coller, G. Voss, D.W. Vaughn, D. Clements, and I. Peters An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model Vaccine 23 2005 4442 4452
156. I.A. Rodenhuis-Zybert, J. Wilschut, and J.M. Smit Dengue virus life cycle: viral and host factors modulating infectivity Cell Mol Life Sci 67 2010 2773 2786
157. R. Rodriguez-Roche, L. Sanchez, Y. Burgher, D. Rosario, M. Alvarez, and G. Kouri Virus role during intraepidemic increase in dengue disease severity Vector Borne Zoonotic Dis 11 2011 675 681
158. M.S. Rolph, A. Zaid, N.E. Rulli, and S. Mahalingam Downregulation of interferon-beta in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6 J Infect Dis 204 2011 489 491
159. L. Rosen Experimental infection of New World monkeys with dengue and yellow fever viruses Am J Trop Med Hyg 7 1958 406
160. F.C. Rossi, R.N. Angerami, E.V. De Paula, F.L. Orsi, D. Shang, and V.M. Del Guercio A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection Transfusion 50 2010 208 212
161. A. Rothman Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms Nat Rev Immunol 11 2011 532 543
162. A. Sabchareon, J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, and P.
163. A. Sabchareon, D. Wallace, C. Sirivichayakul, K. Limkittikul, P. Chanthavanich, and S. Suvannadabba Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial Lancet 2012 [Epub ahead of print]
164. M. Saito, K. Oishi, S. Inoue, E.M. Dimaano, M.T. Alera, A.M. Robles, B.D. Estrella Jr., A. Kumatori, K. Moji, M.T. Alonzo, C.C. Buerano, R.R. Matias, K. Morita, F.F. Natividad, and T. Nagatake Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections Clin Exp Immunol 138 2004 299pp.
165. A. Sakuntabhai, C. Turbpaiboon, I. Casadémont, A. Chuansumrit, T. Lowhnoo, and A. Kajaste-Rudnitski A variant in the CD209 promoter is associated with severity of dengue disease Nat Genet 37 2005 507 513
166. W. Schul, W. Liu, H.Y. Xu, M. Flamand, and S.G. Vasudevan A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs J Infect Dis 195 2007 665 674
167. S. Shresta, K.L. Sharar, D.M. Prigozhin, P.R. Beatty, and E. Harris Murine model for dengue virus-induced lethal disease with increased vascular permeability J Virol 80 2006 10208 10217
168. R.W. Sidwell, J.H. Huffman, G.P. Khare, L.B. Allen, J.T. Witkowski, and R.K. Robins Broad-spectrum antiviral activity of Virazole: 1-beta-D- ribofuranosyl-1,2,4-triazole-3-carboxamide Science 177 1972 705 706
169. B.C. Sierra, R. Alegre, A.B. Pérez, G. García, K. Sturn-Ramirez, and O. Obasanjo HLA-A,-B,-C, and-DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection Hum Immunol 68 2007 531 540
170. B.C. Sierra, G. Garcia, A.B. Perez, L. Morier, M. Alvarez, and G. Kouri Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals Viral Immunol 19 2006 662 668
171. B.C. Sierra, G. Kourí, and M.G. Guzmán Race: a risk factor for dengue hemorrhagic fever Arch Virol 152 2007 533 542
172. S. Simasathien, S.J. Thomas, V. Watanaveeradej, A. Nisalak, C. Barberousse, and B.L. Innis Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children Am J Trop Med Hyg 78 2008 426 433
173. C.P. Simmons, J.J. Farrar, V. Nguyen v, and B. Wills Dengue N Engl J Med 366 2012 1423 1432
174. M. Simmons, G.S. Murphy, T. Kochel, K. Raviprakash, and C.G. Hayes Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine Am J Trop Med Hyg 65 2001 420 426
175. N. Sorvillo, W. Pos, L.M. van den Berg, R. Fijnheer, L. Martinez-Pomares, and T.B. Geijtenbeek The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells Blood 119 2012 3828 3835
176. R. Soundravally, and S.L. Hoti Immunopathogenesis of dengue hemorrhagic fever and shock syndrome: Role of TAP and HPA gene polymorphism Hum Immunol 68 2007 973 979
177. R. Soundravally, and S.L. Hoti Polymorphisms of the TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection Scand J Immunol 67 2008 618
178. R. Soundravally, and S.L. Hoti Significance of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in susceptibility to dengue viral infection J Clin Immunol 28 2008 256 262
179. D.G. Souza, C.T. Fagundes, L.P. Sousa, F.A. Amaral, R.S. Souza, and A.L. Souza Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection Proc Natl Acad Sci U S A 106 2009 14138 14143
180. D.A. Stein, C.Y. Huang, S. Silengo, A. Amantana, S. Crumley, and R.E. Blouch Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus J Antimicrob Chemother 62 2008 555 565
181. D.A. Stein, and P.Y. Shi Nucleic acid-based inhibition of flavivirus infections Front Biosci 13 2008 1385 1395
182. H.A.F. Stephens, R. Klaythong, M. Sirikong, D.W. Vaughn, S. Green, and S. Kalayanarooj HLA-A and-B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais Tissue Antigens 60 2002 309 318
183. A.J. Stevens, M.E. Gahan, S. Mahalingam, and P.A. Keller The medicinal chemistry of dengue fever J Med Chem 52 2009 7911 7926
184. W. Sun, D. Cunningham, S.S. Wasserman, J. Perry, J.R. Putnak, and K.H. Eckels Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults Hum Vaccin 5 2009 33 40
185. W. Sun, R. Edelman, N. Kanesa-Thasan, K.H. Eckels, J.R. Putnak, and A.D. King Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates Am J Trop Med Hyg 69 2003 24 31
186. B. Tassaneetrithep, T.H. Burgess, A. Granelli-Piperno, C. Trumpfheller, J. Finke, and W. Sun DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells J Exp Med 197 2003 823 829
187. S.M. Tomlinson, R.D. Malmstrom, and S.J. Watowich New approaches to structure-based discovery of dengue protease inhibitors Infect Disord Drug Targets 9 2009 327 343
188. V. Tricou, N.N. Minh, J. Farrar, H.T. Tran, and C.P. Simmons Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue PLoS Negl Trop Dis 5 2011 e1309
189. A. Tuiskunen, V. Monteil, S. Plumet, L. Boubis, M. Wahlström, and V. Duong Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome Arch Virol 156 2011 2023 2032
190. S. Ubol, W. Phuklia, S. Kalayanarooj, and N. Modhiran Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies J Infect Dis 201 2010 923 935
191. Y. van Kooyk, and T.B.H. Geijtenbeek DC-SIGN: escape mechanism for pathogens Nat Rev Immunol 3 2003 697 709
192. D. Vaughn, S. Green, S. Kalayanarooj, B. Innis, S. Nimmannitya, and S. Suntayakorn Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity J Infect Dis 181 2000 2 9
193. S. Vejbaesya, P. Luangtrakool, K. Luangtrakool, S. Kalayanarooj, D.W. Vaughn, and T.P. Endy TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais J Infect Dis 199 2009 1442 1448
194. T.T. Vu, E.C. Holmes, V. Duong, T.Q. Nguyen, T.H. Tran, and M. Quail Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia PLoS Negl Trop Dis 4 2010 e757
195. S. Wang, R. He, J. Patarapotikul, B.L. Innis, and R. Anderson Antibody-enhanced binding of dengue-2 virus to human platelets Virology 213 1995 254 257
196. V. Watanaveeradej, S. Simasathien, A. Nisalak, T.P. Endy, R.G. Jarman, and B.L. Innis Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants Am J Trop Med Hyg 85 2011 341 351
197. A.A. Watson, A.A. Lebedev, B.A. Hall, A.E. Fenton-May, A.A. Vagin, and W. Dejnirattisai Structural flexibility of the macrophage dengue virus receptor CLEC5A J Biol Chem 286 2011 24208 24218
198. D. Watts, K. Porter, P. Putvatana, B. Vasquez, C. Calampa, and C. Hayes Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever Lancet 354 1999 1431 1434
199. D.P. Webster, J. Farrar, and S. Rowland-Jones Progress towards a dengue vaccine Lancet Infect Dis 9 2009 678 687
200. K. Whitby, T.C. Pierson, B. Geiss, K. Lane, M. Engle, and Y. Zhou Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo J Virol 79 2005 8698 8706
201. L.J. White, M.M. Parsons, A.C. Whitmore, B.M. Williams, A. de Silva, and R.E. Johnston An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice J Virol 81 2007 10329 10339
202. WHO Dengue and Dengue Haemorrhagic Fever Vol. Fact Sheet 117 2009 World Health Organisation Geneva
203. K.L. Williams, S. Zompi, P.R. Beatty, and E. Harris A mouse model for studying dengue virus pathogenesis and immune response Ann N Y Acad Sci 1171 2009 E12 E23
204. M.R. Wise de Valdez, D. Nimmo, J. Betz, H.-F. Gong, A.A. James, and L. Alphey Genetic elimination of dengue vector mosquitoes Proc Natl Acad Sci U S A 108 2011 4772 4775
205. K.L. Wong, W. Chen, T. Balakrishnan, Y.X. Toh, K. Fink, and S.-C. Wong Susceptibility and response of human blood monocyte subsets to primary dengue virus infection PLoS One 7 2012 e36435
206. S.-J.L. Wu, G. Grouard-Vogel, W. Sun, J.R. Mascola, E. Brachtel, and R. Putvatana Human skin Langerhans cells are targets of dengue virus infection Nat Med 6 2000 816 820
207. Z. Xu, J.S. Smith, J. Tian, and A.P. Byrnes Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor Mol Ther 18 2010 609 616
208. K.D. Yang, C.S. Lee, and M.F. Shaio A higher production of platelet activating factor in ex vivo heterologously secondary dengue-2 virus infections Acta Microbiol Immunol Hung 42 1995 403 407
209. L.E. Yauch, and S. Shresta Mouse models of dengue virus infection and disease Antiviral Res 80 2008 87 93
210. Z. Yin, S.J. Patel, W.L. Wang, G. Wang, W.L. Chan, and K.R. Rao Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead Bioorg Med Chem Lett 16 2006 36 39
211. Z. Yin, S.J. Patel, W.L. Wang, W.L. Chan, K.R. Ranga Rao, and G. Wang Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors Bioorg Med Chem Lett 16 2006 40 43
212. X.G. Zhang, P.W. Mason, E.J. Dubovi, X. Xu, N. Bourne, and R.W. Renshaw Antiviral activity of geneticin against dengue virus Antiviral Res 83 2009 21 27
213. X. Zheng, D. Chung, T.K. Takayama, E.M. Majerus, J.E. Sadler, and K. Fujikawa Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura J Biol Chem 276 2001 41059 41063
214. Z. Zhou, M. Khaliq, J.E. Suk, C. Patkar, L. Li, and R.J. Kuhn Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein ACS Chem Biol 3 2008 765 775
215. Z. Zhou, T.C. Nguyen, P. Guchhait, and J.F. Dong Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura Semin Thromb Hemost 36 2010 71 81
216. S. Zompi, and E. Harris Animal models of dengue virus infection Viruses 4 2012 62 82